A Network Pharmacology-Based Analysis of Multi-Target, Multi-Pathway, Multi-Compound Treatment for Ovarian Serous Cystadenocarcinoma

Overview

Journal Clin Drug Investig

Date 2018 Aug 12

PMID 30097905

Citations 9

Authors

Dan-Dan Xiong

Yue Qin

Wen-Qing Xu

Rong-Quan He

Hua-Yu Wu

Dan-Min Wei

Jing-Jing Zeng

Yi-Wu Dang

Gang Chen

Affiliations

Soon will be listed here.

Abstract

Background And Objectives: Pharmacological control against ovarian serous cystadenocarcinoma has received increasing attention. The purpose of this study was to investigate multi-drug treatments as synergetic therapy for ovarian serous cystadenocarcinoma and to explore their mechanisms of action by the network pharmacology method.

Methods: Genes acting on ovarian serous cystadenocarcinoma were first collected from GEPIA and DisGeNET. Gene Ontology annotation, Kyoto Encyclopedia of Genes and Genomes pathway, Reactome pathway, and Disease Ontology analyses were then conducted. A connectivity map analysis was employed to identify compounds as treatment options for ovarian serous cystadenocarcinoma. Targets of these compounds were obtained from the Search Tool for Interacting Chemicals (STITCH). The intersections between the ovarian serous cystadenocarcinoma-related genes and the compound targets were identified. Finally, the Kyoto Encyclopedia of Genes and Genomes and Reactome pathways in which the overlapped genes participated were selected, and a correspondence compound-target pathway network was constructed.

Results: A total of 541 ovarian serous cystadenocarcinoma-related genes were identified. The functional enrichment and pathway analyses indicated that these genes were associated with critical tumor-related pathways. Based on the connectivity map analysis, five compounds (resveratrol, MG-132, puromycin, 15-delta prostaglandin J2, and valproic acid) were determined as treatment agents for ovarian serous cystadenocarcinoma. Next, 48 targets of the five compounds were collected. Following mapping of the 48 targets to the 541 ovarian serous cystadenocarcinoma-related genes, we identified six targets (PTGS1, FOS, HMOX1, CASP9, PPARG, and ABCB1) as therapeutic targets for ovarian serous cystadenocarcinoma by the five compounds. By analysis of the compound-target pathway network, we found the synergistic anti-ovarian serous cystadenocarcinoma potential and the underlying mechanisms of action of the five compounds.

Conclusion: In summary, latent drugs against ovarian serous cystadenocarcinoma were acquired and their target actions and pathways were determined by the network pharmacology strategy, which provides a new prospect for medicamentous therapy for ovarian serous cystadenocarcinoma. However, further in-depth studies are indispensable to increase the validity of this study.

Citing Articles

: An overview on Bioactive Compounds and Anticancer Mechanisms from a Traditional Medicinal Plant to Modern Investigation.

Zhang M, Ji X, Li Y, Chen X, Wu X, Tan R Mini Rev Med Chem. 2024; 24(12):1162-1176.

PMID: 38288817 DOI: 10.2174/0113895575271848231116095447.

Deciphering neuroprotective mechanism of nitroxoline in cerebral ischemia: network pharmacology and molecular modeling-based investigations.

Vadak N, Borkar M, Bhatt L Mol Divers. 2024; 28(6):3993-4015.

PMID: 38233690 DOI: 10.1007/s11030-023-10791-8.

Integrative Investigation Reveals the Host-Virus Interactions in Repurposed Drugs Against SARS-CoV-2.

Yu W, Bai Y, Raha A, Su Z, Geng F Front Bioinform. 2022; 1:763540.

PMID: 36303774 PMC: 9580895. DOI: 10.3389/fbinf.2021.763540.

Alzheimer-Compound Identification Based on Data Fusion and forgeNet_SVM.

Yang B, Bao W, Hong S Front Aging Neurosci. 2022; 14:931729.

PMID: 35959292 PMC: 9357977. DOI: 10.3389/fnagi.2022.931729.

A New Prospect for the Treatment of Nephrotic Syndrome Based on Network Pharmacology Analysis.

Varghese R, Majumdar A Curr Res Physiol. 2022; 5:36-47.

PMID: 35098155 PMC: 8783131. DOI: 10.1016/j.crphys.2021.12.004.

References

Kaldawy A, Segev Y, Lavie O, Auslender R, Sopik V, Narod S . Low-grade serous ovarian cancer: A review. Gynecol Oncol. 2016; 143(2):433-438. DOI: 10.1016/j.ygyno.2016.08.320. View

Li J, Fadare O, Xiang L, Kong B, Zheng W . Ovarian serous carcinoma: recent concepts on its origin and carcinogenesis. J Hematol Oncol. 2012; 5:8. PMC: 3328281. DOI: 10.1186/1756-8722-5-8. View

Bachmayr-Heyda A, Aust S, Auer K, Meier S, Schmetterer K, Dekan S . Integrative Systemic and Local Metabolomics with Impact on Survival in High-Grade Serous Ovarian Cancer. Clin Cancer Res. 2016; 23(8):2081-2092. DOI: 10.1158/1078-0432.CCR-16-1647. View

Bowtell D, Bohm S, Ahmed A, Aspuria P, Bast Jr R, Beral V . Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer. 2015; 15(11):668-79. PMC: 4892184. DOI: 10.1038/nrc4019. View

Jayson G, Kohn E, Kitchener H, Ledermann J . Ovarian cancer. Lancet. 2014; 384(9951):1376-88. DOI: 10.1016/S0140-6736(13)62146-7. View

Hopkins A . Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol. 2008; 4(11):682-90. DOI: 10.1038/nchembio.118. View

Kibble M, Saarinen N, Tang J, Wennerberg K, Makela S, Aittokallio T . Network pharmacology applications to map the unexplored target space and therapeutic potential of natural products. Nat Prod Rep. 2015; 32(8):1249-66. DOI: 10.1039/c5np00005j. View

Li S, Zhang B . Traditional Chinese medicine network pharmacology: theory, methodology and application. Chin J Nat Med. 2013; 11(2):110-20. DOI: 10.1016/S1875-5364(13)60037-0. View

Yu G, Zhang Y, Ren W, Dong L, Li J, Geng Y . Network pharmacology-based identification of key pharmacological pathways of Yin-Huang-Qing-Fei capsule acting on chronic bronchitis. Int J Chron Obstruct Pulmon Dis. 2017; 12:85-94. PMC: 5191847. DOI: 10.2147/COPD.S121079. View

10.

Qi Q, Li R, Li H, Cao Y, Bai M, Fan X . Identification of the anti-tumor activity and mechanisms of nuciferine through a network pharmacology approach. Acta Pharmacol Sin. 2016; 37(7):963-72. PMC: 4933762. DOI: 10.1038/aps.2016.53. View

11.

Azmi A . Adopting network pharmacology for cancer drug discovery. Curr Drug Discov Technol. 2012; 10(2):95-105. DOI: 10.2174/1570163811310020002. View

12.

Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z . GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017; 45(W1):W98-W102. PMC: 5570223. DOI: 10.1093/nar/gkx247. View

13.

Pinero J, Bravo A, Queralt-Rosinach N, Gutierrez-Sacristan A, Deu-Pons J, Centeno E . DisGeNET: a comprehensive platform integrating information on human disease-associated genes and variants. Nucleic Acids Res. 2016; 45(D1):D833-D839. PMC: 5210640. DOI: 10.1093/nar/gkw943. View

14.

Yu G, Wang L, Han Y, He Q . clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012; 16(5):284-7. PMC: 3339379. DOI: 10.1089/omi.2011.0118. View

15.

Wu G, Dawson E, Duong A, Haw R, Stein L . ReactomeFIViz: a Cytoscape app for pathway and network-based data analysis. F1000Res. 2014; 3:146. PMC: 4184317. DOI: 10.12688/f1000research.4431.2. View

16.

Musa A, Ghoraie L, Zhang S, Glazko G, Yli-Harja O, Dehmer M . A review of connectivity map and computational approaches in pharmacogenomics. Brief Bioinform. 2017; 18(5):903. PMC: 6113891. DOI: 10.1093/bib/bbx023. View

17.

Szklarczyk D, Santos A, von Mering C, Jensen L, Bork P, Kuhn M . STITCH 5: augmenting protein-chemical interaction networks with tissue and affinity data. Nucleic Acids Res. 2015; 44(D1):D380-4. PMC: 4702904. DOI: 10.1093/nar/gkv1277. View

18.

Kim S, Thiessen P, Bolton E, Chen J, Fu G, Gindulyte A . PubChem Substance and Compound databases. Nucleic Acids Res. 2015; 44(D1):D1202-13. PMC: 4702940. DOI: 10.1093/nar/gkv951. View

19.

Anda-Jauregui G, Guo K, McGregor B, Hur J . Exploration of the Anti-Inflammatory Drug Space Through Network Pharmacology: Applications for Drug Repurposing. Front Physiol. 2018; 9:151. PMC: 5838628. DOI: 10.3389/fphys.2018.00151. View

20.

Cao H, Li S, Xie R, Xu N, Qian Y, Chen H . Exploring the Mechanism of Dangguiliuhuang Decoction Against Hepatic Fibrosis by Network Pharmacology and Experimental Validation. Front Pharmacol. 2018; 9:187. PMC: 5844928. DOI: 10.3389/fphar.2018.00187. View